OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY

被引：0
|
作者：
Young, LeAnne [1 ]
Finnigan, Shanda [2 ]
Streicher, Howard [2 ]
Chen, Helen [2 ]
Murray, James [2 ]
Sen, H. Nida [1 ]
Sharon, Elad [2 ]
机构：
[1] NEI, Cleveland, OH USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页码：A386 / A387
页数：2
相关论文
共 50 条
  • [1] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [2] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    [J]. UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [3] Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
    Cheng, Xuyang
    Dai, Hehua
    Wan, Ni
    Moore, Yolonda
    Vankayalapati, Ramakrishna
    Dai, Zhenhua
    [J]. TRANSPLANTATION, 2009, 87 (12) : 1778 - 1786
  • [4] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
  • [5] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    [J]. ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [6] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [7] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [8] Clinical Significance of Programmed Death-1 Ligand-2 in Esophageal Cancer: Comparison with Programmed Death-1 Ligand-1
    Okadome, Kazuo
    Baba, Yoshifumi
    Yagi, Taisuke
    Kiyozumi, Yuki
    Eto, Kojiro
    Hiyoshi, Yukiharu
    Ishimoto, Takatsugu
    Nagai, Yohei
    Iwagami, Shiro
    Miyamoto, Yuji
    Yoshida, Naoya
    Baba, Hideo
    [J]. CANCER SCIENCE, 2018, 109 : 414 - 414
  • [9] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [10] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns
    Nishino, Mizuki
    Hatabu, Hiroto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14)
12345